phenyl valerate profile

Phenyl valerate is an ester formed from the reaction of valeric acid (pentanoic acid) and phenol. It is a colorless liquid with a fruity odor. Phenyl valerate has been studied for its potential therapeutic effects, particularly in the context of inflammation and pain. It has been shown to exhibit anti-inflammatory activity in animal models, potentially through its ability to inhibit the production of inflammatory mediators such as prostaglandins. However, research on phenyl valerate is limited, and further studies are needed to fully understand its pharmacological profile and potential clinical applications. The compound's importance lies in its potential as a starting material for the synthesis of other pharmaceutical compounds, and its use in fragrance formulations. The study of phenyl valerate is driven by its potential as a therapeutic agent, its role in fragrance chemistry, and its potential as a building block for other compounds.'

ID Source	ID
PubMed CID	29950
SCHEMBL ID	643462
MeSH ID	M0142686

Synonym
pentanoic acid, phenyl ester
valeric acid, phenyl ester
phenyl valerate
FT-0695354
phenyl pentanoate
AKOS003028181
20115-23-5
einecs 243-521-0
STL477958
SCHEMBL643462
MVIMPQVBUPCHEV-UHFFFAOYSA-N
phenyl pentanoate #
F2158-2213
DTXSID50173930
pentanoic acid, phenyl ester;valeric acid, phenyl ester
BCP26152
phenylvalerate

Research Excerpts

Overview

Phenyl valerate (PV) is a neutral substrate for measuring the PVase activity of neuropathy target esterase (NTE) NTE is a key molecular event of organophosphorus-induced delayed neuropathy.

Excerpt	Reference	Relevance
"Phenyl valerate (PV) is a neutral substrate for measuring the PVase activity of neuropathy target esterase (NTE), a key molecular event of organophosphorus-induced delayed neuropathy. "	( Interactions of human acetylcholinesterase with phenyl valerate and acetylthiocholine: Thiocholine as an enhancer of phenyl valerate esterase activity. Estévez, J; Sogorb, MÁ; Terol, M; Vilanova, E, 2022)	2.42
"Phenyl valerate (PV) is a substrate for measuring the PVase activity of neuropathy target esterase (NTE), a key molecular event of organophosphorus-induced delayed neuropathy. "	( Interactions of human butyrylcholinesterase with phenylvalerate and acetylthiocholine as substrates and inhibitors: kinetic and molecular modeling approaches. Costa Franca, TC; Estévez, J; Mangas, I; Rodrigues de Souza, F; Romo, M; Vilanova, E, 2019)	1.96

Bioavailability

Excerpt	Reference	Relevance
" The comparison of the results between the intact cells and the lysed cells suggests that the plasma membrane could act as a barrier that reduced the bioavailability of mipafox to PVases."	( Hydrolyzing activities of phenyl valerate sensitive to organophosphorus compounds paraoxon and mipafox in human neuroblastoma SH-SY5Y cells. Del Río, E; Estévez, J; González-González, M; Sogorb, MA; Vilanova, E, 2018)	0.78

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (10.00)	18.7374
1990's	4 (20.00)	18.2507
2000's	5 (25.00)	29.6817
2010's	7 (35.00)	24.3611
2020's	2 (10.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (9.52%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	19 (90.48%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
phenylacetic acid phenylacetic acid : A monocarboxylic acid that is toluene in which one of the hydrogens of the methyl group has been replaced by a carboxy group.	2.44	2	benzenes; monocarboxylic acid; phenylacetic acids	allergen; Aspergillus metabolite; auxin; EC 6.4.1.1 (pyruvate carboxylase) inhibitor; Escherichia coli metabolite; human metabolite; plant growth retardant; plant metabolite; Saccharomyces cerevisiae metabolite; toxin
chlorpyrifos Chlorpyrifos: An organothiophosphate cholinesterase inhibitor that is used as an insecticide and as an acaricide.. chlorpyrifos : An organic thiophosphate that is O,O-diethyl hydrogen phosphorothioate in which the hydrogen of the hydroxy group has been replaced by a 3,5,6-trichloropyridin-2-yl group.	2.05	1	chloropyridine; organic thiophosphate	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; environmental contaminant; insecticide; xenobiotic
4-phenylbutyric acid 4-phenylbutyric acid: RN refers to the parent cpd. 4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.	1.93	1	monocarboxylic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor; prodrug
phenylmethylsulfonyl fluoride Phenylmethylsulfonyl Fluoride: An enzyme inhibitor that inactivates IRC-50 arvin, subtilisin, and the fatty acid synthetase complex.. phenylmethanesulfonyl fluoride : An acyl fluoride with phenylmethanesulfonyl as the acyl group.	2.1	1	acyl fluoride	serine proteinase inhibitor
isoflurophate Isoflurophate: A di-isopropyl-fluorophosphate which is an irreversible cholinesterase inhibitor used to investigate the NERVOUS SYSTEM.	3.63	9	dialkyl phosphate
serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.	7.01	1	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
tri-o-cresyl phosphate tri-o-cresyl phosphate: see also related IMOL S-140	3.1	1
paraoxon [no description available]	8.26	6	aryl dialkyl phosphate; organophosphate insecticide	EC 3.1.1.7 (acetylcholinesterase) inhibitor; mouse metabolite
mipafox mipafox: structure	8.52	8	phosphoramide
benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide Benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(N,N-dimethyl-N-2-propenyl-), Dibromide: Proposed cholinesterase inhibitor.	2.1	1
4-nitrophenyl acetate [no description available]	2.03	1	C-nitro compound; phenyl acetates
acetylthiocholine Acetylthiocholine: An agent used as a substrate in assays for cholinesterases, especially to discriminate among enzyme types.	7.69	2
o,o-diethyl o-3,5,6-trichloro-2-pyridyl phosphate [no description available]	2.05	1
gold Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.	2.03	1	copper group element atom; elemental gold
phenyl acetate phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.	2.41	1	benzenes; phenyl acetates
thiocholine Thiocholine: A mercaptocholine used as a reagent for the determination of CHOLINESTERASES. It also serves as a highly selective nerve stain.	7.41	1
valerates Valerates: Derivatives of valeric acid, including its salts and esters.	5.99	20	short-chain fatty acid anion; straight-chain saturated fatty acid anion	plant metabolite
nitrophenols Nitrophenols: PHENOLS carrying nitro group substituents.	2.03	1

Condition	Relationship Strength	Studies
Absence Seizure [description not available]	2.31	1
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	2.31	1
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	7.17	1
Cognitive Decline [description not available]	2.13	1
Bilateral Headache [description not available]	2.13	1
Nervous System Disorders [description not available]	3.36	2
Headache The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.	2.13	1
Nervous System Diseases Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.	3.36	2
Cognitive Dysfunction Diminished or impaired mental and/or intellectual function.	2.13	1
Autosomal Dominant Hereditary Spastic Paraplegia [description not available]	2.05	1
Anterior Horn Cell Disease [description not available]	2.05	1
Spastic Paraplegia, Hereditary A group of inherited diseases that share similar phenotypes but are genetically diverse. Different genetic loci for autosomal recessive, autosomal dominant, and x-linked forms of hereditary spastic paraplegia have been identified. Clinically, patients present with slowly progressive distal limb weakness and lower extremity spasticity. Peripheral sensory neurons may be affected in the later stages of the disease. (J Neurol Neurosurg Psychiatry 1998 Jan;64(1):61-6; Curr Opin Neurol 1997 Aug;10(4):313-8)	2.05	1
Motor Neuron Disease Diseases characterized by a selective degeneration of the motor neurons of the spinal cord, brainstem, or motor cortex. Clinical subtypes are distinguished by the major site of degeneration. In AMYOTROPHIC LATERAL SCLEROSIS there is involvement of upper, lower, and brainstem motor neurons. In progressive muscular atrophy and related syndromes (see MUSCULAR ATROPHY, SPINAL) the motor neurons in the spinal cord are primarily affected. With progressive bulbar palsy (BULBAR PALSY, PROGRESSIVE), the initial degeneration occurs in the brainstem. In primary lateral sclerosis, the cortical neurons are affected in isolation. (Adams et al., Principles of Neurology, 6th ed, p1089)	2.05	1
Elevated Cholesterol [description not available]	1.93	1
Hypercholesterolemia A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.	1.93	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2	1

phenyl valerate

Cross-References

Synonyms (17)

Research Excerpts

Overview

Bioavailability

Research

Studies (20)

Market Indicators

Research Demand Index: 19.36

Study Types

phenyl valerate

Cross-References

Synonyms (17)

Research Excerpts

Overview

Bioavailability

Research

Studies (20)

Market Indicators

Research Demand Index: 19.36

Study Types

Related Drugs (18)

Related Conditions (16)